A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/11/3692 |
| _version_ | 1797547653981011968 |
|---|---|
| author | Matteo Dragani Giovanna Rege Cambrin Paola Berchialla Irene Dogliotti Gianantonio Rosti Fausto Castagnetti Isabella Capodanno Bruno Martino Marco Cerrano Dario Ferrero Carlo Gambacorti-Passerini Monica Crugnola Chiara Elena Massimo Breccia Alessandra Iurlo Daniele Cattaneo Sara Galimberti Antonella Gozzini Monica Bocchia Francesca Lunghi Michele Cedrone Nicola Sgherza Luigia Luciano Sabina Russo Marco Santoro Valentina Giai Giovanni Caocci Luciano Levato Elisabetta Abruzzese Federica Sora Giuseppe Saglio Carmen Fava |
| author_facet | Matteo Dragani Giovanna Rege Cambrin Paola Berchialla Irene Dogliotti Gianantonio Rosti Fausto Castagnetti Isabella Capodanno Bruno Martino Marco Cerrano Dario Ferrero Carlo Gambacorti-Passerini Monica Crugnola Chiara Elena Massimo Breccia Alessandra Iurlo Daniele Cattaneo Sara Galimberti Antonella Gozzini Monica Bocchia Francesca Lunghi Michele Cedrone Nicola Sgherza Luigia Luciano Sabina Russo Marco Santoro Valentina Giai Giovanni Caocci Luciano Levato Elisabetta Abruzzese Federica Sora Giuseppe Saglio Carmen Fava |
| author_sort | Matteo Dragani |
| collection | DOAJ |
| description | Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported—281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months—65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression. |
| first_indexed | 2024-03-10T14:47:11Z |
| format | Article |
| id | doaj.art-d16234c7f9484b51bb54d54daf16809a |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T14:47:11Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-d16234c7f9484b51bb54d54daf16809a2023-11-20T21:17:53ZengMDPI AGJournal of Clinical Medicine2077-03832020-11-01911369210.3390/jcm9113692A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani0Giovanna Rege Cambrin1Paola Berchialla2Irene Dogliotti3Gianantonio Rosti4Fausto Castagnetti5Isabella Capodanno6Bruno Martino7Marco Cerrano8Dario Ferrero9Carlo Gambacorti-Passerini10Monica Crugnola11Chiara Elena12Massimo Breccia13Alessandra Iurlo14Daniele Cattaneo15Sara Galimberti16Antonella Gozzini17Monica Bocchia18Francesca Lunghi19Michele Cedrone20Nicola Sgherza21Luigia Luciano22Sabina Russo23Marco Santoro24Valentina Giai25Giovanni Caocci26Luciano Levato27Elisabetta Abruzzese28Federica Sora29Giuseppe Saglio30Carmen Fava31Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyHematology Unit, Department of Biotechnology and Health Sciences, University of Turin, 10126 Turin, ItalyInstitute of Hematology “L. e A. Seràgnoli”, University of Bologna, 40138 Bologna, ItalyInstitute of Hematology “L. e A. Seràgnoli”, University of Bologna, 40138 Bologna, ItalyHematology Unit, Azienda Unità Sanitaria Locale-IRCCS, 42123 Reggio Emilia, ItalyHematology Unit, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyHematology Unit, Department of Biotechnology and Health Sciences, University of Turin, 10126 Turin, ItalyHematology Unit, Department of Biotechnology and Health Sciences, University of Turin, 10126 Turin, ItalyHematology Division, San Gerardo Hospital, 20900 Monza, ItalyDivision of Hematology, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyDepartment of Hematology Oncology, Foundation IRCCS Policlinico San Matteo, University of Pavia, 27100 Pavia, ItalyDepartment of Translational and Precision Medicine, Sapienza University, 00161 Rome, ItalyHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, ItalyHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, ItalyHematology Department, University of Pisa, 56126 Pisa, ItalyHematology Division, Policlinico Careggi di Firenze, 50139 Firenze, ItalyHematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, 53100 Siena, ItalyHematology and Bone Marrow Transplant Unit, San Raffaele Scientific Institute IRCCS, 20132 Milano, ItalyHematology Division, Az. Ospedaliera San Giovanni Addolorata, 00184 Rome, ItalyDivision of Hematology, IRCCS Ospedale Casa Sollievo Sofferenza, 71043 San Giovanni Rotondo, ItalyHematology Unit, “Federico II” Hospital, University of Naples, 80131 Napoli, ItalyDepartment of Internal Medicine, AOU Policlinico di Messina, 98124 Messina, ItalyHematology Unit, University of Palermo, 90127 Palermo, ItalyHematology Unit, Antonio e Biagio e Cesare Arrigo Hospital, 15121 Alessandria, ItalyHematology Unit, Department of Medical Sciences, University of Cagliari, 09121 Cagliari, ItalyDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, ItalyHematology Unit, S. Eugenio Hospital, Tor Vergata University, 00144 Rome, ItalyHematology Unit, Fondazione Policlinico Universitario Gemelli IRCCS, 00168 Rome, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, ItalySuccessful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported—281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months—65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.https://www.mdpi.com/2077-0383/9/11/3692chronic myeloid leukemiatreatment-free remissionmolecular monitoring |
| spellingShingle | Matteo Dragani Giovanna Rege Cambrin Paola Berchialla Irene Dogliotti Gianantonio Rosti Fausto Castagnetti Isabella Capodanno Bruno Martino Marco Cerrano Dario Ferrero Carlo Gambacorti-Passerini Monica Crugnola Chiara Elena Massimo Breccia Alessandra Iurlo Daniele Cattaneo Sara Galimberti Antonella Gozzini Monica Bocchia Francesca Lunghi Michele Cedrone Nicola Sgherza Luigia Luciano Sabina Russo Marco Santoro Valentina Giai Giovanni Caocci Luciano Levato Elisabetta Abruzzese Federica Sora Giuseppe Saglio Carmen Fava A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation Journal of Clinical Medicine chronic myeloid leukemia treatment-free remission molecular monitoring |
| title | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation |
| title_full | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation |
| title_fullStr | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation |
| title_full_unstemmed | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation |
| title_short | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation |
| title_sort | retrospective analysis about frequency of monitoring in italian chronic myeloid leukemia patients after discontinuation |
| topic | chronic myeloid leukemia treatment-free remission molecular monitoring |
| url | https://www.mdpi.com/2077-0383/9/11/3692 |
| work_keys_str_mv | AT matteodragani aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT giovannaregecambrin aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT paolaberchialla aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT irenedogliotti aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT gianantoniorosti aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT faustocastagnetti aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT isabellacapodanno aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT brunomartino aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT marcocerrano aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT darioferrero aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT carlogambacortipasserini aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT monicacrugnola aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT chiaraelena aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT massimobreccia aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT alessandraiurlo aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT danielecattaneo aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT saragalimberti aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT antonellagozzini aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT monicabocchia aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT francescalunghi aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT michelecedrone aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT nicolasgherza aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT luigialuciano aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT sabinarusso aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT marcosantoro aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT valentinagiai aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT giovannicaocci aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT lucianolevato aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT elisabettaabruzzese aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT federicasora aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT giuseppesaglio aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT carmenfava aretrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT matteodragani retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT giovannaregecambrin retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT paolaberchialla retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT irenedogliotti retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT gianantoniorosti retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT faustocastagnetti retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT isabellacapodanno retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT brunomartino retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT marcocerrano retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT darioferrero retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT carlogambacortipasserini retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT monicacrugnola retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT chiaraelena retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT massimobreccia retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT alessandraiurlo retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT danielecattaneo retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT saragalimberti retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT antonellagozzini retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT monicabocchia retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT francescalunghi retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT michelecedrone retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT nicolasgherza retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT luigialuciano retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT sabinarusso retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT marcosantoro retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT valentinagiai retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT giovannicaocci retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT lucianolevato retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT elisabettaabruzzese retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT federicasora retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT giuseppesaglio retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation AT carmenfava retrospectiveanalysisaboutfrequencyofmonitoringinitalianchronicmyeloidleukemiapatientsafterdiscontinuation |